TAILIEUCHUNG - Báo cáo y học: "Omalizumab: Practical considerations regarding the risk of anaphylaxis"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Omalizumab: Practical considerations regarding the risk of anaphylaxis. | Kim et al. Allergy Asthma Clinical Immunology 2010 6 32 http content 6 1 32 ALLERGY ASTHMA CLINICAL IMMUNOLOGY REVIEW Open Access Omalizumab Practical considerations regarding the risk of anaphylaxis Harold L Kim1 Richard Leigh2 Allan Becker3 Abstract Omalizumab has demonstrated efficacy among patients with moderate to severe persistent allergic asthma whose symptoms are inadequately controlled with other controller agents. This therapy is generally well tolerated but there are some safety considerations the most important of which is the rare but potentially life-threatening occurrence of omalizumab-associated anaphylaxis. In Canada data from the manufacturer of omalizumab indicate that the frequency of anaphylaxis attributed to Xolair in post-marketing use is approximately . Other researchers including the American Omalizumab Joint Task Force OJTF have suggested a lower overall frequency of . This paper provides a summary of the epidemiologic research carried out to date and presents a concise practical set of recommendations for the prevention monitoring and management of omalizumab-associated anaphylaxis. Prevention tips include advice on patient education measures concomitant medications and optimal administration. For the first three injections the recommendation is to monitor in clinic for two hours after the omalizumab injection for subsequent injections the monitoring period should be 30 minutes or an appropriate time agreed upon by the individual patient and healthcare professional. In the event that a patient does experience omalizumab-associated anaphylaxis the paper provides recommendations for handling the situation in-clinic and recommendations on how to counsel patients to recognize the potential signs and symptoms in the community and react appropriately. Introduction Omalizumab a recombinant humanized monoclonal anti-IgE antibody is indicated for patients with moderate to severe persistent allergic asthma whose .

TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.